These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 36634615)
1. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer. Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615 [TBL] [Abstract][Full Text] [Related]
2. Genomic features and its potential implication in bone oligometastatic NSCLC. Liao R; Yi G; Shen L; Zhang X; Xu Z; Peng Y; Yang Z BMC Pulm Med; 2023 Feb; 23(1):59. PubMed ID: 36755257 [TBL] [Abstract][Full Text] [Related]
3. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency. Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993 [TBL] [Abstract][Full Text] [Related]
4. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Deek MP; Van der Eecken K; Phillips R; Parikh NR; Isaacsson Velho P; Lotan TL; Kishan AU; Maurer T; ; Boutros PC; Hovens C; Abramowtiz M; Pollack A; Desai N; Stish B; Feng FY; Eisenberger M; Carducci M; Pienta KJ; Markowski M; Paller CJ; Antonarakis ES; Berlin A; Ost P; Tran PT Eur Urol; 2021 Nov; 80(5):632-640. PubMed ID: 33419682 [TBL] [Abstract][Full Text] [Related]
5. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations. Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523 [TBL] [Abstract][Full Text] [Related]
6. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917 [TBL] [Abstract][Full Text] [Related]
7. Clinical and Pathological Characteristics of Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460 [No Abstract] [Full Text] [Related]
8. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647 [TBL] [Abstract][Full Text] [Related]
9. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma. Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269 [TBL] [Abstract][Full Text] [Related]
11. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC. Arolt C; Dugan M; Wild R; Richartz V; Holz B; Scheel AH; Brägelmann J; Wagener-Ryczek S; Merkelbach-Bruse S; Wolf J; Buettner R; Catanzariti L; Scheffler M; Hillmer AM J Thorac Oncol; 2023 Nov; 18(11):1550-1567. PubMed ID: 37473958 [TBL] [Abstract][Full Text] [Related]
12. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053 [TBL] [Abstract][Full Text] [Related]
13. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993 [TBL] [Abstract][Full Text] [Related]
14. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Vokes NI; Galan Cobo A; Fernandez-Chas M; Molkentine D; Treviño S; Druker V; Qian Y; Patel S; Schmidt S; Hong L; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Negrao MV; Gibbons DL; Vaporciyan A; Le X; Wu J; Zhang J; Rigney U; Iyer S; Dean E; Heymach JV Clin Cancer Res; 2023 Dec; 29(23):4958-4972. PubMed ID: 37733794 [TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database. Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448 [TBL] [Abstract][Full Text] [Related]